Translational studies on myeloid leukemia cells and clinical studies on APL patients demonstrated that, point mutations in the ligand-binding domain (E domain) of RAR is, as well, another possible resistance mechanism [111,122]. The gene discussed is RARA; the disease is acute promyelocytic leukemia.